Intensity Therapeutics Inc Quick Ratio (INTS) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Intensity Therapeutics Inc   (NASDAQ: INTS)

Intensity Therapeutics Inc 's Quick Ratio

INTS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 3.29 above Intensity Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 72 other companies have achieved higher Quick Ratio than Intensity Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 644 to 890.

Explain Quick Ratio?
How much Cash & cash equivalents INTS´s has?
What are INTS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/INTS/financial-strength
https://api.csimarket.com/api/v1/companies/INTS/fundamentals
https://api.csimarket.com/api/v1/companies/INTS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
INTS Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 13.44 %
Y / Y Cash & cash equivalent Change 20.19 %
Quick Ratio MRQ 3.29
INTS's Total Ranking # 890
Seq. Current Liabilities Change 15.01 %
Seq. Cash & cash equivalent Change -10.59 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 73
Healthcare Sector # 334
Overall Market # 890


Quick Ratio Statistics
High Average Low
9.24 2.52 0.04
(Sep 30 2023)   (Jun 30 2023)




Financial Statements
Intensity Therapeutics Inc 's Current Liabilities $ 3 Millions Visit INTS's Balance sheet
Intensity Therapeutics Inc 's Cash & cash equivalent $ 8 Millions Visit INTS's Balance sheet
Source of INTS's Sales Visit INTS's Sales by Geography


Cumulative Intensity Therapeutics Inc 's Quick Ratio

INTS's Quick Ratio for the trailling 12 Months

INTS Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 4.76 %
Y / Y Cash & cash equivalent TTM Growth 213.46 %
Quick Ratio TTM 4.36
Total Ranking TTM # 3604
Seq. Current Liabilities TTM Growth 3.43 %
Seq. Cash & cash equivalent TTM Growth 3.68 %

Quick ratio ranking by company, industry and sector >> Back to INTS Financial Strength Comparisons >> Go to Compare INTS Quick Ratio to its Competitors

On the trailing twelve months basis INTS Cash & cash equivalent grew by 20.19 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Intensity Therapeutics Inc 's Quick Ratio to 4.36, above INTS average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Intensity Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2967 to 3604.

Explain Quick Ratio?
How much Cash & cash equivalents INTS´s has?
What are INTS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 863
Within the Market # 3604


trailing twelve months Quick Ratio Statistics
High Average Low
4.35 1.97 0.96
(Jun 30 2026)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Protara Therapeutics Inc  8.83 $ 127.050  Millions$ 14.391  Millions
Immunovant Inc   6.94 $ 722.274  Millions$ 104.022  Millions
Repligen Corp  6.87 $ 862.979  Millions$ 125.686  Millions
Compass Therapeutics Inc   6.69 $ 163.058  Millions$ 24.368  Millions
Black Diamond Therapeutics Inc   6.62 $ 102.030  Millions$ 15.405  Millions
Krystal Biotech Inc   6.45 $ 916.484  Millions$ 142.144  Millions
Voyager Therapeutics Inc   6.35 $ 106.806  Millions$ 16.813  Millions
Cabaletta Bio Inc   6.33 $ 299.383  Millions$ 47.332  Millions
Cognition Therapeutics inc   6.00 $ 30.758  Millions$ 5.128  Millions
Replimune Group Inc   5.57 $ 307.833  Millions$ 55.271  Millions
Denali Therapeutics Inc   5.42 $ 516.196  Millions$ 95.258  Millions
In8bio Inc   5.32 $ 13.973  Millions$ 2.628  Millions
Scholar Rock Holding Corp  5.16 $ 413.599  Millions$ 80.124  Millions
Revolution Medicines Inc   4.81 $ 3,651.385  Millions$ 758.773  Millions
Caribou Biosciences Inc   4.71 $ 94.881  Millions$ 20.144  Millions
Recursion Pharmaceuticals Inc   4.47 $ 549.853  Millions$ 122.918  Millions
Ginkgo Bioworks Holdings Inc   4.33 $ 285.361  Millions$ 65.849  Millions
Fate Therapeutics Inc   4.26 $ 139.132  Millions$ 32.691  Millions
Kymera Therapeutics Inc   4.16 $ 373.374  Millions$ 89.723  Millions
Monte Rosa Therapeutics Inc   4.16 $ 577.726  Millions$ 139.022  Millions
Vir Biotechnology Inc   4.08 $ 454.635  Millions$ 111.332  Millions
Moderna Inc   3.93 $ 7,976.000  Millions$ 2,028.000  Millions
Immunocore Holdings Plc  3.93 $ 901.298  Millions$ 229.619  Millions
Alector Inc   3.92 $ 138.697  Millions$ 35.415  Millions
Dbv Technologies S a   3.89 $ 165.700  Millions$ 42.600  Millions
Regenxbio Inc   3.71 $ 250.976  Millions$ 67.684  Millions
Tenaya Therapeutics Inc   3.55 $ 66.797  Millions$ 18.804  Millions
Intensity Therapeutics Inc   3.29 $ 8.494  Millions$ 2.582  Millions
Adaptive Biotechnologies Corporation  3.02 $ 298.954  Millions$ 98.967  Millions
Atyr Pharma Inc   2.96 $ 48.751  Millions$ 16.463  Millions

Date modified: 2026-11-06T08:52:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.